127 related articles for article (PubMed ID: 15596197)
1. 18F-fluorodeoxyglucose positron emission tomography in evaluation of germ cell tumor after chemotherapy.
Johns Putra L; Lawrentschuk N; Ballok Z; Hannah A; Poon A; Tauro A; Davis ID; Hicks RJ; Bolton DM; Scott AM
Urology; 2004 Dec; 64(6):1202-7. PubMed ID: 15596197
[TBL] [Abstract][Full Text] [Related]
2. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography with conventional assessment by computed tomography scans and serum tumor markers for the evaluation of residual masses in patients with nonseminomatous germ cell carcinoma.
Kollmannsberger C; Oechsle K; Dohmen BM; Pfannenberg A; Bares R; Claussen CD; Kanz L; Bokemeyer C
Cancer; 2002 May; 94(9):2353-62. PubMed ID: 12015760
[TBL] [Abstract][Full Text] [Related]
3. FDG PET for detection and therapy control of metastatic germ cell tumor.
Cremerius U; Effert PJ; Adam G; Sabri O; Zimmy M; Wagenknecht G; Jakse G; Buell U
J Nucl Med; 1998 May; 39(5):815-22. PubMed ID: 9591582
[TBL] [Abstract][Full Text] [Related]
4. [Early prediction of treatment response to high-dose chemotherapy in patients with relapsed germ cell tumors using [18F]FDG-PET, CT or MRI, and tumor marker].
Pfannenberg AC; Oechsle K; Kollmannsberger C; Dohmen BM; Bokemeyer C; Bares R; Vontheim R; Claussen CD
Rofo; 2004 Jan; 176(1):76-84. PubMed ID: 14712410
[TBL] [Abstract][Full Text] [Related]
5. The role of (18)fluoro-2-deoxyglucose positron emission tomography in initial staging and re-staging after chemotherapy for testicular germ cell tumours.
Spermon JR; De Geus-Oei LF; Kiemeney LA; Witjes JA; Oyen WJ
BJU Int; 2002 Apr; 89(6):549-56. PubMed ID: 11942962
[TBL] [Abstract][Full Text] [Related]
6. [18F]Fluorodeoxyglucose positron emission tomography in nonseminomatous germ cell tumors after chemotherapy: the German multicenter positron emission tomography study group.
Oechsle K; Hartmann M; Brenner W; Venz S; Weissbach L; Franzius C; Kliesch S; Mueller S; Krege S; Heicappell R; Bares R; Bokemeyer C; de Wit M;
J Clin Oncol; 2008 Dec; 26(36):5930-5. PubMed ID: 19018083
[TBL] [Abstract][Full Text] [Related]
7. Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse.
Hain SF; O'Doherty MJ; Timothy AR; Leslie MD; Harper PG; Huddart RA
Br J Cancer; 2000 Oct; 83(7):863-9. PubMed ID: 10970686
[TBL] [Abstract][Full Text] [Related]
8. Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma.
De Santis M; Bokemeyer C; Becherer A; Stoiber F; Oechsle K; Kletter K; Dohmen BM; Dittrich C; Pont J
J Clin Oncol; 2001 Sep; 19(17):3740-4. PubMed ID: 11533096
[TBL] [Abstract][Full Text] [Related]
9. Use of fluorodeoxyglucose positron emission tomography scans in patients with advanced germ cell tumour following chemotherapy: single-centre experience with long-term follow up.
Karapetis CS; Strickland AH; Yip D; Steer C; Harper PG
Intern Med J; 2003; 33(9-10):427-35. PubMed ID: 14511195
[TBL] [Abstract][Full Text] [Related]
10. False-positive fluorodeoxyglucose positron emission tomography results after chemotherapy in patients with metastatic seminoma.
Decoene J; Winter C; Albers P
Urol Oncol; 2015 Jan; 33(1):23.e15-23.e21. PubMed ID: 25454484
[TBL] [Abstract][Full Text] [Related]
11. The role of positron emission tomography in germ cell cancer.
De Santis M; Pont J
World J Urol; 2004 Apr; 22(1):41-6. PubMed ID: 15024601
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic value of 18F-FDG positron emission tomography for detection and treatment control of malignant germ cell tumors.
Tsatalpas P; Beuthien-Baumann B; Kropp J; Manseck A; Tiepolt C; Hakenberg OW; Burchert W; Franke WG; Wirth MP
Urol Int; 2002; 68(3):157-63. PubMed ID: 11919460
[TBL] [Abstract][Full Text] [Related]
13. Early prediction of treatment response to high-dose salvage chemotherapy in patients with relapsed germ cell cancer using [(18)F]FDG PET.
Bokemeyer C; Kollmannsberger C; Oechsle K; Dohmen BM; Pfannenberg A; Claussen CD; Bares R; Kanz L
Br J Cancer; 2002 Feb; 86(4):506-11. PubMed ID: 11870528
[TBL] [Abstract][Full Text] [Related]
14. Can we rely on PET in the follow-up of advanced seminoma patients?
Siekiera J; Małkowski B; Jóźwicki W; Jasiński M; Wronczewski A; Pietrzak T; Chmielowska E; Petrus A; Kamecki K; Mikołajczak W; Kraśnicki K; Chłosta P; Drewa T
Urol Int; 2012; 88(4):405-9. PubMed ID: 22507953
[TBL] [Abstract][Full Text] [Related]
15. [Fluorodeoxyglucose (FDO) positron emission tomography (PET) in testicular germ cell tumors in adults: preliminary French clinical evaluation, development of the technique and its clinical applications].
Maszelin P; Lumbroso J; Theodore C; Foehrenbach H; Merlet P; Syrota A
Prog Urol; 2000 Dec; 10(6):1190-9. PubMed ID: 11217558
[TBL] [Abstract][Full Text] [Related]
16. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial.
De Santis M; Becherer A; Bokemeyer C; Stoiber F; Oechsle K; Sellner F; Lang A; Kletter K; Dohmen BM; Dittrich C; Pont J
J Clin Oncol; 2004 Mar; 22(6):1034-9. PubMed ID: 15020605
[TBL] [Abstract][Full Text] [Related]
17. FDG PET is superior to CT in the prediction of viable tumour in post-chemotherapy seminoma residuals.
Becherer A; De Santis M; Karanikas G; Szabó M; Bokemeyer C; Dohmen BM; Pont J; Dudczak R; Dittrich C; Kletter K
Eur J Radiol; 2005 May; 54(2):284-8. PubMed ID: 15837411
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of 18F-FDG PET/CT and CT/MRI with histopathologic correlation in patients undergoing salvage surgery for head and neck squamous cell carcinoma.
Kim SY; Kim JS; Yi JS; Lee JH; Choi SH; Nam SY; Cho KJ; Lee SW; Kim SB; Roh JL
Ann Surg Oncol; 2011 Sep; 18(9):2579-84. PubMed ID: 21409485
[TBL] [Abstract][Full Text] [Related]
19. 18fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: preliminary report of MRC Trial TE22--the NCRI Testis Tumour Clinical Study Group.
Huddart RA; O'Doherty MJ; Padhani A; Rustin GJ; Mead GM; Joffe JK; Vasey P; Harland SJ; Logue J; Daugaard G; Hain SF; Kirk SJ; MacKewn JE; Stenning SP;
J Clin Oncol; 2007 Jul; 25(21):3090-5. PubMed ID: 17634488
[TBL] [Abstract][Full Text] [Related]
20. The role of positron emission tomography in the evaluation of residual masses after chemotherapy for advanced stage seminoma.
Hinz S; Schrader M; Kempkensteffen C; Bares R; Brenner W; Krege S; Franzius C; Kliesch S; Heicappel R; Miller K; de Wit M
J Urol; 2008 Mar; 179(3):936-40; discussion 940. PubMed ID: 18207171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
